Correlation and prognostic significance of p53, p21(WAF1/CIP1) and Ki-67 expression in patients with superficial bladder tumors treated with bacillus Calmette-Guerin intravesical therapy

Journal of Urology

Volumn 161, Issue 3, 1999, Pages 792-798

  Zlotta, Alexandre R ^a   Noel, Jean Christophe ^a   Fayt, Isabelle ^a   Drowart, Annie ^a   Van Vooren, Jean Paul ^a   Huygen, Kris ^a   Simon, Jacques ^a   Schulman, Claude C ^a  

^a ERASME HOSPITAL   (Belgium)

Author keywords

BCG; Bladder cancer; Ki 67; p21; p53

Indexed keywords

BCG VACCINE; KI 67 ANTIGEN; PROTEIN P21; PROTEIN P53; TUMOR MARKER;

ACCURACY; ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER GRADING; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; HUMAN TISSUE; INTRAVESICAL DRUG ADMINISTRATION; MALE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; TREATMENT OUTCOME;

EID: 0032877579     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)61770-1     Document Type: Article

References (28)

1. Nseyo, U. O. and Lamm, D. L.: Therapy of superficial bladder cancer. Sem. Oncol., 23: 598, 1996.
2. Zlotta, A. R., Drowart, A., Van Vooren, J. P., De Cock, M., Pirson, M., Palfliet, K., Jurion, F., Vanonckelen, Simon, J., Schulman, C. C. and Huygen, K.: Evolution and clinical significance of the T-cell proliferative and cytokine response directed against the fibronectin-binding antigen 85 complex of bacillus Calmette-Guérin during intravesical treatment of superficial bladder cancer. J. Urol., 157: 492, 1997.
3. Zlotta, A. R., Drowart, A., Huygen, K., De Bruyn, J., Shekarsarai, H., Decock, M., Pirson, M., Jurion, F., Palfliet, K., Denis, O., Mascart, F., Simon, J., Schulman, C. C. and Van Vooren, J. P.: Humoral response against heat shock proteins and other mycobacterial antigens after intravesical treatment with bacille Calmette-Guerin (BCG) in patients with superficial bladder cancer. Clin. Exp. Immunol., 109: 157, 1997.
4. De Reijke, T. M., De Boer, E. C., Kurth, K. H. and Schammart, D. H. J.: Urinary cytokines during intravesical bacillus Calmette-Guérin therapy for superficial bladder cancer: processing, stability and prognostic value. J. Urol., 155: 477, 1996.
5. Nouri, A. M. E., Darakhshan, F., Cannell, H., Paris, A. M. I. and Oliver, R. T. D.: The relevance of p53 mutations in urological malignancies: possible implications for bladder cancer. Brit. J. Urol., 78: 337, 1996.
6. Moch, H., Saufer, G., Mihatsch, M. J., Gudat, F., Epper, R. and Waldman, F. M.: p53 but not erbB-2 expression is associated with rapid tumor proliferation in urinary bladder cancer. Hum. Path., 25: 1346, 1994.
7. Carson, D. A. and Lois, A.: Cancer progression and p53. Lancet, 346: 1009, 1995.
8. El-Deiry, W., Harper, J., O'Connor, P., Velculescu, V., Canman, C., Jackman, J., Pietenpol, J., Burrell, M., Hill, D., Wang, Y., Wiman, K., Mercer, W., Kastan, M., Kohn, K., Elledge, S., Kinzler, K. and Vogelstein, B.: WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res., 54: 1169, 1994.
9. Jacks, T. and Weinberg, R. A.: Cell-cycle control and its watchmen. Nature, 381: 643, 1996.
10. CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell, 82: 675, 1995.
11. Elbendary, A. A., Cirisano, F. D., Evans, A. C., Davis, P. L., Iglehart, J. D., Marks, J. R. and Berchuck, A.: Relationship between p21 expression and mutation of the p53 tumor suppressor gene in normal and malignant ovarian epithelial cells. Clin. Cancer Res., 2: 1571, 1996.
12. Marchetti, A., Doglioni, C., Barbareschi, M., Buttitta, F., Pellegrini, S., Bertacca, G., Chella, A., Merlo, G., Angeletti, C. A., Palma, P. D. and Bevilacqua, G.: p21 RNA and protein expression in non-small cell lung carcinomas: evidence of p53-independent expression and association with tumoral differentiation. Oncogene, 12: 1319, 1996.
13. Bukholm, I. K., Nesland, J. M., Karesen, R., Jacobsen, U. and Borresen, A. L.: Relationship between abnormal p53 protein and failure to express p21 protein in human breast carcinomas. J. Path., 181: 140, 1997.
14. WAF1 and p53 expression in breast carcinoma: an immunohistochemical study in 261 patients with long-term follow-up. Clin. Cancer Res., 2: 1591, 1996.
15. Ovesen, H., Horn, T. and Steven, K.: Long-term efficacy of intravesical bacillus Calmette-Guérin for carcinoma in situ: relationship of progression to histological response and p53 nuclear accumulation. J. Urol., 157: 1655, 1997.
16. Sarkis, A., Dalbagni, G., Cordon-Cardo, C., Melamed, J., Zhang, Z. F., Steinfeld, J., Fair, W., Herr, H. and Reuter, V.: Association of p53 nuclear overexpression and tumor progression in carcinoma in situ of the bladder. J. Urol., 152: 388, 1994.
17. Raitanen, M. P., Tammela, T. L. J., Kallioinen, M. and Isola, J.: p53 accumulation, deoxyribonucleic acid ploidy and progression of bladder cancer. J. Urol., 157: 1250, 1997.
18. Gardiner, R., Walsh, M., Rahman, A., Samaratunga, G., Seymour, G. and Lavin, M.: Immunohistological expression of p53 in primary pT1 transitional cell bladder cancer in relation to tumour progression. Brit. J. Urol., 73: 526, 1994.
19. Shiina, H., Igawa, M., Nagami, H., Yagi, H., Urakami, S., Yoneda, T., Shirakawa, H., Ishibe, T. and Kawanishi, M.: Immunohistochemical analysis of proliferating cell nuclear antigen, p53 protein and nm23 protein, and nuclear DNA content in transitional cell carcinoma of the bladder. Cancer, 78: 1762, 1996.
20. Ick, K., Schultz, M., Stout, P. and Fan, K.: Significance of p53 overexpression in urinary bladder transitional cell carcinoma in situ before and after bacillus Calmette-Guérin treatment. Urology, 49: 541, 1997.
21. Lacombe, L., Dalbagni, G., Zhang, Z. P., Cordon-Cardo, C., Fair, W. R., Herr, H. W. and Reuter, V. E.: Overexpression of p53 protein in a high-risk population of patients with superficial bladder cancer before and after bacillus Calmette-Guérin therapy: correlation to clinical outcome. J. Clin. Oncol., 14: 2646, 1996.
22. Lebret, T., Becette, V., Gentille, A., Bargaletta, M., Hervé, J. M., Barré, P., Gaudez, F., Lugagne, M. and Botto, H.: Correlation between p53 over expression and response to Calmette-Guérin therapy in a high risk select population of patients with T1G3 bladder cancer. J. Urol., 159: 788, 1998.
23. Pages, F., Flam, T. A., Vieillefond, A., Molinie, V., Abeille, X., Lazar, V., Bressac-de Paillerets, B., Mosseri, V., Zerbib, M., Fridman, W. H., Debré, B. and Thiounn, N.: p53 status does not predict initial clinical response to bacillus Calmette-Guérin therapy in T1 bladder tumors. J. Urol., 159: 1079, 1998.
24. Sjögren, S., Inganas, M., Norberg, T., Lindgren, A., Nordgren, H., Holmberg, L. and Bergh, J.: The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. J. Natl. Cancer Inst., 88: 173, 1996.
25. WAF1/CIP1 in primary bladder tumors. Oncol. Res., 8: 409, 1996.
26. Gomyo, Y., Ikeda, M., Osaki, M., Tatebe, S., Tsujitani, S., Ikeguchi, M., Kaibara, N. and Ito, H.: Expression of p21 (WAF1/CIP1/SDI1) but not p53 protein, is a factor in the survival of patients with advanced gastric carcinoma. Cancer, 79: 2067, 1997.
27. Komiya, T., Hosono, Y., Hirashima, T., Masuda, N., Yasumitsu, T., Nakagawa, K., Kikui, M., Ohno, A., Fukuoaka, M. and Kawase, I.: p21 expression as a predictor for favorable prognosis in squamous cell carcinoma of the lung. Clin. Cancer Res., 3: 1831, 1997.
28. Popov, Z., Hoznek, A., Colombel, M., Bastuji-Garin, S., Lefrere-Belda, Bellot, J., Abbou, C. C., Mazerolles, C. and Chopin, D. K.: The prognostic value of p53 nuclear overexpression and MIB-1 as a proliferative marker in transitional cell carcinoma of the bladder. Cancer, 80: 1472, 1997.